In the last trading session, 2.08 million shares of the Immunome Inc (NASDAQ:IMNM) were traded, and its beta was 1.91. Most recently the company’s share price was $11.22, and it changed around $0.35 or 3.22% from the last close, which brings the market valuation of the company to $950.06M. IMNM currently trades at a discount to its 52-week high of $30.96, offering almost -175.94% off that amount. The share price’s 52-week low was $8.97, which indicates that the current value has risen by an impressive 20.05% since then. We note from Immunome Inc’s average daily trading volume that its 10-day average is 1.48 million shares, with the 3-month average coming to 988.32K.

Immunome Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IMNM as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Immunome Inc is expected to report earnings per share of -0.67 for the current quarter.

Immunome Inc (NASDAQ:IMNM) trade information

Instantly IMNM has showed a green trend with a performance of 3.22% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 12.44 on recent trading dayincreased the stock’s daily price by 9.81%. The company’s shares are currently up 5.65% year-to-date, but still up 8.72% over the last five days. On the other hand, Immunome Inc (NASDAQ:IMNM) is 5.25% up in the 30-day period. We can see from the shorts that 10.54 million shares have been sold at a short interest cover period of 12.51 day(s).

The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to increase their stock price by 51.22% from its current value. Analyst projections state that IMNM is forecast to be at a low of $23 and a high of $23.

Immunome Inc (IMNM) estimates and forecasts

The year-over-year growth rate is expected to be -32.90%, down from the previous year.

Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 3.16M in revenue for the current quarter. 6 analysts expect Immunome Inc to make 515.67k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.83M and 1.03M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -17.51%. Forecasts for the next quarter put sales growth at -49.89%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -48.48%. Immunome Inc earnings are expected to increase by 17.82% in 2025, but the outlook is positive 16.01% per year for the next five years.

IMNM Dividends

Immunome Inc’s next quarterly earnings report is expected to be released in March.

Immunome Inc (NASDAQ:IMNM)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 14.94% of Immunome Inc shares, and 64.32% of them are in the hands of institutional investors. The stock currently has a share float of 75.62%. Immunome Inc stock is held by 175.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 8.1579% of the shares, which is about 4.89 million shares worth $59.16 million.

FMR LLC, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30, holds the second largest percentage of outstanding shares.